A Phase 2 interventional study of Valbenazine and Placebo oral capsule in Tourette Syndrome, sponsored by Neurocrine Biosciences. Terminated at 49 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-05-17.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.
Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 33rd largest by enrollment of the 105 interventional ones that give a count, is one of 12 that started in 2018, is one of 26 in phase 2, and was the 87th registered.
240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.
Browse Tourette Syndrome studies →20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 12–17
University of Minnesota · Sites in United States
Ages 12–21
University of Utah · Sites in United States
Ages 8–17
Vanderbilt University Medical Center · Sites in United States
Ages 11–17 · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 0–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 30 · Phase 3 12 · Phase 4 8
First in 1988; this study’s year is marked. 12 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 36 across 183 interventional studies indexed under Tourette Syndrome.
Median enrollment 33 across the 105 interventional studies, 90 across the 33 observational. Of the 106 that completed or were terminated, 45 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 139 have an industry lead sponsor. The 10 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
Neurocrine Biosciences has 8 studies filed under Tourette Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Tourette Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05558566Yale UniversityNeurofeedback From the Supplementary Motor Area for Tourette Syndrome | 2026-12-20 |
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
| NCT04851678Vanderbilt University Medical CenterLongitudinal Impact of Stressors in Adults With Tourette Syndrome | 2027-03-01 |
| NCT05126888Neurothera Labs Inc.SCI-110 in the Treatment of Tourette Syndrome | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 139 studies in Tourette Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received valbenazine once daily for up to 12 weeks, depending on if and when randomization occured. The starting dose was 20 mg for participants \<50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for participants \<50 kg and 80 mg for participants ≥50 kg to achieve an optimal dose of valbenazine for each participant.
Drug: Valbenazine
Participants received placebo (matching valbenazine) once daily from randomization (Week 8, 10, or 12) through Week 36. Randomization into this arm occurred after treatment with valbenazine once daily through randomization.
Drug: Placebo oral capsule
Participants received their optimized dose of valbenazine once daily from randomization (Week 8, 10, or 12) through Week 36. Randomization into this arm occurred after treatment with valbenazine once daily through randomization.
Drug: Valbenazine
vesicular monoamine transporter 2 (VMAT2) inhibitor
Also known as: NBI-98854
non-active dosage form
Time to Loss of Treatment Response
Loss of treatment response during the withdrawal period was defined as: 2 consecutive visits with 1) an increase in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) of greater than 35% or 7 points from the randomized withdrawal period baseline and 2) an increase in CGI-Tics-Severity score of ≥2 points from the randomized withdrawal period baseline; or discontinuation due to lack of efficacy or a treatment-emergent adverse event (TEAE) of worsening of tics. Median (lower and upper quartiles) Kaplan-Meier estimates for the time to loss of treatment response were not able to be calculated because of the low incidence of loss of treatment response events.
Time frame: Randomization (Week 8, 10 or 12) through Week 36
Change From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the YGTSS TTS
The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity. Least-squares mean were estimated using a mixed-effects model for repeated measures.
Time frame: Randomization Baseline (Week 8, 10 or 12); 8 weeks post-randomization
Change From Randomization Baseline to the Week 36 Visit in the YGTSS TTS
The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity.
Time frame: Randomization Baseline (Week 8, 10 or 12); Week 36
Change From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the CGI-Tics-Severity Score
The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.
Time frame: Randomization Baseline (Week 8, 10 or 12); 8 weeks post-randomization
Change From Randomization Baseline to the Week 36 Visit in the CGI-Tics-Severity Score
The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.
Time frame: Randomization Baseline (Week 8, 10 or 12); Week 36
Up to 180 male and female pediatric subjects between 6 and 17 years of age (inclusive) with a DSM-IV or -V diagnosis of TS were planned to be enrolled. A total of 81 subjects were enrolled. The first and last participants were enrolled on April 17 2018 and May 7 2019, respectively.
| Milestone | Pre-randomization Valbenazine | Randomized Placebo | Randomized Valbenazine |
|---|---|---|---|
| Started | 81 | 0 | 0 |
| Safety analysis set | 80 | 0 | 0 |
| Completed | 57 | 0 | 0 |
| Not completed | 24 | 0 | 0 |
| Withdrew: Adverse event | 12 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 | 0 |
| Milestone | Pre-randomization Valbenazine | Randomized Placebo | Randomized Valbenazine |
|---|---|---|---|
| Started | 0 | 26 | 26 |
| Completed | 0 | 9 | 9 |
| Not completed | 0 | 17 | 17 |
| Withdrew: Adverse event | 0 | 2 | 4 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 2 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 10 | 10 |
Loss of treatment response during the withdrawal period was defined as: 2 consecutive visits with 1) an increase in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) of greater than 35% or 7 points from the randomized withdrawal period baseline and 2) an increase in CGI-Tics-Severity score of ≥2 points from the randomized withdrawal period baseline; or discontinuation due to lack of efficacy or a treatment-emergent adverse event (TEAE) of worsening of tics. Median (lower and upper quartiles) Kaplan-Meier estimates for the time to loss of treatment response were not able to be calculated because of the low incidence of loss of treatment response events.
| Days | Randomized Placebo | Randomized Valbenazine |
|---|---|---|
| Time to Loss of Treatment Response | NA (NA to NA) | NA (NA to NA) |
The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity. Least-squares mean were estimated using a mixed-effects model for repeated measures.
| units on a scale | Randomized Placebo | Randomized Valbenazine |
|---|---|---|
| Change From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the YGTSS TTS | 3.8 ± 1.6 | -1.0 ± 1.7 |
The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity.
| units on a scale | Randomized Placebo | Randomized Valbenazine |
|---|---|---|
| Change From Randomization Baseline to the Week 36 Visit in the YGTSS TTS | 0.6 ± 12.06 | 0.1 ± 8.21 |
The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.
| units on a scale | Randomized Placebo | Randomized Valbenazine |
|---|---|---|
| Change From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the CGI-Tics-Severity Score | 0.7 ± 0.2 | -0.1 ± 0.2 |
The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.
| units on a scale | Randomized Placebo | Randomized Valbenazine |
|---|---|---|
| Change From Randomization Baseline to the Week 36 Visit in the CGI-Tics-Severity Score | 0.1 ± 0.78 | 0.2 ± 1.30 |
Collected over Pre-randomization valbenazine group: from baseline up to randomization (Week 8, 10 or 12) or end of participation in subjects who did not randomize, up to 16 weeks. Randomized placebo and valbenazine groups: from randomization (Week 8, 10 or 12) up to Week 40. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pre-randomization Valbenazine | 0/80 (0%) | 1/80 (1.3%) | 41/80 (51.3%) |
| Randomized Placebo | 0/26 (0%) | 2/26 (7.7%) | 12/26 (46.2%) |
| Randomized Valbenazine | 0/26 (0%) | 2/26 (7.7%) | 14/26 (53.8%) |
| Event | Pre-randomization Valbenazine | Randomized Placebo | Randomized Valbenazine |
|---|---|---|---|
| AkathisiaNervous system disorders | 0/80 | 0/26 | 1/26 |
| TicPsychiatric disorders | 0/80 | 0/26 | 1/26 |
| Obsessive-compulsive disorderPsychiatric disorders | 0/80 | 1/26 | 0/26 |
| Tourette's disorderCongenital, familial and genetic disorders | 0/80 | 1/26 | 0/26 |
| Enterovirus infectionInfections and infestations | 1/80 | 0/26 | 0/26 |
| Event | Pre-randomization Valbenazine | Randomized Placebo | Randomized Valbenazine |
|---|---|---|---|
| SomnolenceNervous system disorders | 20/80 | 0/26 | 1/26 |
| NauseaGastrointestinal disorders | 4/80 | 1/26 | 4/26 |
| IrritabilityGeneral disorders | 6/80 | 4/26 | 4/26 |
| AnxietyPsychiatric disorders | 1/80 | 4/26 | 0/26 |
| FatigueGeneral disorders | 10/80 | 1/26 | 0/26 |
| VomitingGastrointestinal disorders | 4/80 | 0/26 | 3/26 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/80 | 1/26 | 3/26 |
| HeadacheNervous system disorders | 9/80 | 3/26 | 2/26 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 7/80 | 1/26 | 1/26 |
| Gastroenteritis viralInfections and infestations | 0/80 | 2/26 | 1/26 |
The full analysis set includes all subjects who were randomized to a treatment group and had at least one post-randomization visit where loss of treatment response was able to be assessed.
| Age, Continuous(years) | Randomized Placebo | Randomized Valbenazine | Total |
|---|---|---|---|
| Mean | 12.7 ± 2.7 | 12.8 ± 3.1 | 12.8 ± 2.9 |
| Sex: Female, Male(Participants) | Randomized Placebo | Randomized Valbenazine | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 21 | 24 | 45 |
| Ethnicity (NIH/OMB)(Participants) | Randomized Placebo | Randomized Valbenazine | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 6 | 14 |
| Not Hispanic or Latino | 18 | 20 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Randomized Placebo | Randomized Valbenazine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 22 | 24 | 46 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Jul 2019, 14 months.
Results were first posted in May 2022, 2 years 10 months after primary completion. A results delay was requested in Jan 2020.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine